ABSORB EXTEND Clinical Investigation

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 812 participants.

Also called NCT01023789

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 812 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01023789
  • ANZCTR ACTRN12610000131055
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Denmark, France, Germany, India, Israel, Italy, Japan, Malaysia, Netherlands, New Zealand, Poland, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01023789. Allocation not applicable; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2016-10 (actual). Results posted on 2017-12-18.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ABSORB EXTEND Clinical Investigation
Acronym
ABSORB EXTEND
Condition
Myocardial Ischemia
Condition
Coronary Artery Stenosis
Condition
Coronary Disease
Condition
Coronary Restenosis
Condition
Cardiovascular Disease
Intervention (Device)
ABSORB BVS
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct01023789
Content hash
264562cb002ea631fdabbbf096d34a1ba69dfd7e82f2b6dd8bcb2b1078985ad9